Figenshau R S, Basler J W, Ritter J H, Siegel C L, Simon J A, Dierks S M
Department of Surgery, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA.
J Urol. 1998 Mar;159(3):711-3.
Renal medullary carcinoma is a rare and extremely aggressive neoplasm that almost always develops in young patients with sickle cell trait. To our knowledge all cases to date have been metastatic at surgical resection. Pathological examination reveals an aggressive tumor mainly involving the renal medulla with a varied morphology. The prognosis is dismal. Mean survival from the time of resection is 15 weeks (range 2 to 52). The disease course has not been altered by surgery, radiotherapy or various regimens of chemotherapeutic agents.
We add to the literature our experience treating renal medullary carcinoma in 2 cases and review the existing literature on this disease.
Both patients whom we treated died of the disease, as have the other 35 patients described in the literature.
A high index of suspicion may lead to earlier diagnosis and treatment, and survival of patients with renal medullary carcinoma.
肾髓质癌是一种罕见且极具侵袭性的肿瘤,几乎总是发生于具有镰状细胞性状的年轻患者。据我们所知,迄今为止所有病例在手术切除时均已发生转移。病理检查显示为一种主要累及肾髓质、形态多样的侵袭性肿瘤。预后很差。自切除时起的平均生存期为15周(范围2至52周)。手术、放疗或各种化疗方案均未改变疾病进程。
我们将治疗2例肾髓质癌的经验补充到文献中,并对有关该疾病的现有文献进行综述。
我们治疗的2例患者均死于该疾病,文献中描述的其他35例患者亦是如此。
高度的怀疑指数可能会使肾髓质癌患者得以更早诊断和治疗,从而提高生存率。